Futura Strikes Deal With Menarini To Commercialize MED3000 ED Gel In South Korea

South Korean erectile dysfunction sufferers may soon be able to acess Futura Medical's drug-free MED3000 treatment thanks to a deal with Menarini Korea Limited, a wholly owned subsidiary of Italy’s Menarini Group, for exclusive commercialization rights in the country. 

Flag of South Korea flies in front of a blue sky
• Source: Shutterstock

Menarini Korea Limited, a wholly owned subsidiary of Italy’s Menarini Group, has struck a deal with UK R&D specialist Futura Medical plc for the exclusive rights to commercialize the latter’s topical, gel-based erectile dysfunction treatment MED3000 in South Korea.

Under the terms of the agreement, Menarini will be responsible for all local MED3000 development, regulatory approvals, product launch and marketing,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Asia

More from Geography